Digest Network Come funziona
Network
/
Società
LE
Non verificato

LEO Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

54 comunicati stampa

Guarda tutti i comunicati
09/07/2026
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Industria
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
25/06/2026
Biotecnologia
Salute
Sanità
Farmaceutica
Scienza
Vetrine/Shopping
Giovani
Medicina - Varie
Eventi
Industria
LEO Pharma to Showcase New Data Highlighting the Burden and Unmet Needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
05/05/2026
Multimedialità
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
LEO Pharma Delivers 9% Revenue Growth at CER in Q1 2026 and Strengthens Innovation Pipeline
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
30/04/2026
Mercato azionario
Mercato del lavoro
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Salute
Farmaceutica
LEO Pharma Bolsters Rare Skin Disease Focus Through Acquisition of Replay Gene Therapy Platform
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
17/04/2026
Industria
Salute
Medicina - Varie
Sanità
Scienza
Farmaceutica
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
15/04/2026
Industria
Salute
Igiene alimentare
Vetrine/Shopping
Giovani
Infanzia
Farmaceutica
Biotecnologia
LEO Pharma Announces FDA Acceptance of Supplemental NDA for ANZUPGO® (delgocitinib) Cream for the Treatment of Chronic Hand Eczema in Children Aged 12-17
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
27/03/2026
Industria
Eventi
Salute
Medicina - Varie
Sanità
Scienza
Farmaceutica
LEO Pharma Announces New Long-Term Data for SPEVIGO® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
20/03/2026
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Farmaceutica
LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
05/03/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
“It’s GO time”: LEO Pharma launches Direct-to-Consumer campaign to raise awareness of Chronic Hand Eczema
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0